Also antibody-cytokine fusion proteins enhance the direct antitumour effect of the antibody and concentrate the cytokine (e.g. IL-2) in the tumour microenvironment without causing severe toxic side effects of systemic high-dose cytokine administration. Here, IL2 is linked to neoplasm.